002172 Jiangsu Aoyang Health Industry
- 3.40
- +0.04+1.19%
Jiangsu Aoyang Health Industry News
Aoyang Technology (002172) Quarterly Report Review: Performance Meets Expectations and Maintains Recommendations
Australian Science and Technology (002172) medium report comments: revenue in line with the expected gross profit margin has declined
Australian Science and Technology (002172) Quarterly report comments: the first quarter results are in line with expected maintenance recommendations
Australian Science and Technology (002172) Annual report comments: viscose price increase performance greatly increase medical service business steadily
Australian Science and Technology (002172) first report: viscose staple fiber holds high prosperity to support the company's profit improvement
Comments on Australian Science and Technology (002172) Annual report: the volume and price of viscose staple fiber increased significantly compared with the same period last year.
Comments on Australian Science and Technology (002172) Annual report: the volume and price of viscose staple fiber rose faster than expected
Comments on Australian Science and Technology (002172) Annual report: the volume and price of viscose staple fiber increases steadily in medical business.
Aoyang Science and Technology (002172) follow-up report: viscose staple fiber high prosperity guarantee performance medical and health business develops smoothly
[Societe Generale Securities] Australian Science and Technology follow-up report: viscose staple fiber high prosperity guarantee performance, medical and health business development smoothly
澳洋科技(002172)季报点评：三季报业绩超预期 维持推荐
澳洋科技(002172)深度研究：双轮驱动的粘胶行业龙头
澳洋科技(002172)季报点评：一季度及半年度业绩基本符合预期
澳洋科技(002172)年报点评：看好公司轻重结合的康复扩张模式
澳洋科技(002172)年报点评：双主业驱动下业绩大幅提高
【群益证券(香港)】澳洋科技:Q1业绩预盈,行业供需格局向好,维持买入评级
【申万宏源】澳洋科技:业绩符合预期,粘胶业务景气周期向上、医疗业务将加速推进,维持买入评级
澳洋科技(002172)点评：Q1业绩预盈 行业供需格局向好 维持买入评级
【上海证券】澳洋科技2015年年报点评:双主业驱动下业绩大幅提高
澳洋科技(002172)点评：业绩符合预期 粘胶业务景气周期向上、医疗业务将加速推进 维持买入评级
Analysis
Price Target
No Data
No Data